NONPARTISAN · SOURCED FROM CONGRESS.GOV, OPENFEC, SENATE & HOUSE CLERKS · UPDATED REGULARLY
119th Congress · House bill · Last action Jan 9, 2025
BillsForeign Trade and International FinanceH.R. 322Congress.gov ↗
H.R. 322In CommitteeForeign Trade and International Finance

Democrats propose tariff requirements for imported goods and products.

Sponsor: Rep. Suozzi, Thomas R. (D-NY)3 cosponsorsIntroduced Jan 9, 2025
In plain English

A plain-English summary isn’t available for this bill yet.

Where it is in the process

Introduced
Jan 9
House committee
Jan 9
3
House floor
-
4
Senate
-
5
Signed
-
What happens next: Sits in committee. Needs a markup or favorable report to advance to the House floor.

Community vote

How readers of ThePolitibase feel about this bill. Reader sentiment only — not a scientific poll, and not a measure of public opinion.

- support · - oppose · - total

District map

Scroll or use + / − to zoom, drag to pan. Search a ZIP or district to jump there.
Now showing: community pulse — reader sentiment, not a scientific poll
Hover a district to see the member and how they voted.
Add your voice
Reader sentiment only — not a scientific poll, one vote per network. Find your district above (by ZIP or code), then weigh in.
No district selected

Sponsor

Cosponsors (3)

NR
RR
AR
1 Democrat, 2 Republicans (of 3 shown).

Activity timeline

Jan 9
Jan 9, 2025
Referred to the House Committee on Ways and Means.
Jan 9
Jan 9, 2025
Introduced in House
Jan 9
Jan 9, 2025
Introduced in House
Read the bill text
Official text via Congress.gov. Opens in a new tab.
Read full text →

Full action log

All 3 recorded actions since introduction · Source: Congress.gov
Jan 9
HOUSEReferred to the House Committee on Ways and Means.
Jan 9
Introduced in House
Jan 9
Introduced in House

All 3 cosponsors

1 Democrat · 2 Republicans
Democrats (1)
Republicans (2)

In the news

Pirtobrutinib Plus Venetoclax Shows Promising Results in CLL - Oncology News Central
Pirtobrutinib Plus Venetoclax/Rituximab Improves PFS in Pretreated CLL - CancerNetwork
Fixed-Duration Pirtobrutinib/Venetoclax/Rituximab Drives PFS Benefit in R/R CLL - OncLive
Consternation as Congress proposal for autonomous prescribing AI coincides with the haphazard cuts at the FDA - Nature
Track this bill
Get an alert when it moves to the next stage or gets a vote.
Share
Embed this tracker on your site
Paste this HTML into your blog post or website to show a live tracker for this bill.
The embedded card updates automatically as the bill progresses. Preview →